ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Want to see AVBP full AI Analyst Report?
AVBP Stock Chart & Stats
$29.64
$0.14(0.52%)
At close: 4:00 PM EST
$29.64
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$16.10 - $32.14
Previous CloseN/A
Volume49.09K
Average Volume (3M)455.62K
Market Cap
$1.41B
Enterprise Value$1.35B
Total Cash (Recent Filing)$326.38M
Total Debt (Recent Filing)$419.00K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 18, 2026EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding46,574,930
10 Day Avg. Volume515,032
30 Day Avg. Volume455,618
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.91
Forecast
1Y Price Target
$44.56Price Target Upside50.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strengthened Balance SheetExtremely low debt and a materially expanded asset base provide financial flexibility and lower refinancing risk. This durable strength supports multi‑period R&D spending and late‑stage trials without immediate credit pressure, enabling strategic optionality for partnerships or staged development.
Promising Next‑generation Oncology PipelinePreclinical AACR data underpinning pivotal Phase 3 plans and a differentiated ADC (ARR‑002) signal durable scientific merit. Clinical advancement of firmonertinib and a partnered ADC franchise can expand addressable markets, diversify risk across assets, and support long‑term commercial potential if trials validate findings.
Equity Financing Capacity Via ATM ProgramAn established $250M at‑the‑market program provides a persistent, management‑controlled source of capital to fund development milestones. This durable financing flexibility reduces the chance of emergency financings and supports multi‑quarter project execution cadence, improving program continuity.
Bears Say
Pre‑revenue Business ModelNo product revenue leaves long‑term value entirely contingent on successful clinical development and regulatory approval. This structural lack of operating income increases binary outcome risk, lengthens time to self‑sustaining cash generation, and maintains dependence on external funding over multiple quarters.
High And Persistent Cash BurnSustained negative operating and free cash flow reflects real cash outlays to advance trials and operations. Persistent burn will deplete liquidity over time absent revenue or large financings, pressuring runway and potentially forcing dilutive raises or program prioritization that can delay development timelines.
Dependence On Public Capital And Dilution RiskWhile the ATM provides capital access, reliance on equity markets creates dilution risk and ties funding to market conditions. Repeated issuances can erode shareholder value and constrain long‑term returns if clinical milestones don't translate into revenue growth, making financing strategy a structural vulnerability.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $16.10 and its highest was $32.14 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.41B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 77 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on May 11, 2026. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.895 by -$0.065.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.97.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 46,574,930 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.895. Following the earnings report the stock price went down -0.172%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.56 (50.32% Upside)
$44.56 (50.32% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 35.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.37%
12-Months-Change
Fundamentals
Return on Equity
-48.98%
Trailing 12-Months
Asset Growth
62.09%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$44.56
▲(50.32% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
9.57% Insiders
11.74% Mutual Funds
56.55% Other Institutional Investors
12.40% Public Companies and
Individual Investors